Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives
Dados Bibliográficos
| AUTOR(ES) | |
|---|---|
| EDITOR(ES) | A. A. Arantes |
| ANO | 2012 |
| TIPO | Book |
| PERIÓDICO | Revista da Associação Médica Brasileira (English Edition) |
| ISSN | 2255-4823 |
| EDITORA | Elsevier BV |
| DOI | 10.1016/s2255-4823(12)70190-x |
| ADICIONADO EM | 2025-08-29 |
| MD5 |
339dbd00bb7c7be7ab15570905d983a1
|
Resumo
This review discusses the current status and future perspectives of epidermal growth factor receptor (EGFR) inhibitors in non-small cell lung cancer (NSCLC). EGFR mutations are found in a significant subset of NSCLC patients, particularly those with adenocarcinoma histology, never-smoking history, and Asian ethnicity. EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, and afatinib, have demonstrated significant clinical benefit in patients with EGFR-mutant NSCLC, leading to improved progression-free survival and overall survival compared to standard chemotherapy. The review addresses mechanisms of resistance to EGFR-TKIs, including the emergence of secondary mutations like T790M, and explores strategies to overcome resistance, such as the development of next-generation EGFR-TKIs and combination therapies. The future of EGFR-targeted therapy in NSCLC involves identifying predictive biomarkers for response, developing more effective and less toxic therapies, and personalizing treatment strategies based on individual patient characteristics.